Don't think it says "fail", but definitely doesn't say 'success'
Market just says , no money to be made from vaccines for a long time if.
They will need to prioritise now. in the immunotherapies. The company does not earn enough to fund everything in the pipe.
Short to medium term its all adapt and medical devices.
No need to pump immunology for now, it is what it is.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-61
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |